Menu
Welcome to BONESUPPORT, you have come on to the US page, would you like to stay or be redirected to the International site?

BONESUPPORT AB is a Scandinavian orthobiologics company that develops and markets CERAMENT®, an innovative range of radiopaque injectable osteoconductive and drug-eluting bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months.

Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery.

Video Interview

Our CEO Emil Billbäck has been interviewed by EFN (Ekonomi- och Finansnyheter) today. See the whole interview in Swedish here.

11th January 2019

Latest Press Release

BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications

4th January 2019

BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications

Lund, Sweden, 8:00 CET, January 4 2019 – BONESUPPORT an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that will take place March 1, 2019. Annelie Aava Vikner starts in a new position as the company´s Executive Vice President Global Marketing & Communications. Annelie Aava Vikner has more than 15 years of experience from various marketing management positions at Medtronic, the USA founded healthcare technology company. Most recently she functioned as Senior Strategy & Marketing Manager Austria, Switzerland, Benelux, Greece, Israel & Nordic.

“Annelie Aava Vikner will be an important addition to the BONESUPPORT leadership team. Her experience will be of value for the exciting time ahead of us. Additionally, I want to thank Linda Butcher for her achievements as Chief Marketing Officer. Linda takes on the role as Vice President of Training & Events” says Emil Billbäck, BONESUPPORT CEO.

 

About BONESUPPORT

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit www.bonesupport.com for more information.

BONESUPPORT® and CERAMENT® are registered trademarks

 

For more information contact:

 

BONESUPPORT AB

Emil Billbäck, CEO

+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46(0) 46 286 53 70
ir@bonesupport.com

 

 

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir

+44 (0)20 7638 9571

bonesupport@citigatedewerogerson.com

 

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on 4 January 2019.

 

Downloads

Press release PDF (0 bytes)


NON-EXCLUSIVE U.S. DIRECT DISTRIBUTOR:

CERAMENT® | BONE VOID FILLER, formerly sold exclusively in the U.S. through a distributor, is now available directly from BONESUPPORT, the developer and sole manufacturer of CERAMENT.

To avoid a disruption in CERAMENT supply, please review important facts about the transition here.